[Latest] Point-Of-Care Molecular Diagnostics Market to Grow Rapidly, Hitting US$ 17.94 Bn by 2034 at 8.70% CAGR, due to Growing Clinical Need for Rapid, Decentralized Genetic Testing for Infectious Disease Decisions, says ZMR

NEW YORK, USA, July 14, 2026 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Point-Of-Care Molecular Diagnostics Market By Product Type (Instruments and Analyzers, Reagents and Consumables, Software and Services), By Technology (Polymerase Chain Reaction, Isothermal Amplification, Hybridization, Next-Generation Sequencing), By Application (Infectious Disease Testing, Oncology and Cancer Screening, Cardiology, Neurological Disorders, Sexual Health and Sexually Transmitted Infections), By End-User (Hospitals and Clinics, Diagnostic Laboratories, Ambulatory Care Centers, Home Care Settings, Pharmacies), By Distribution Channel (Direct Sales, Distributors and Dealers, Online Retail), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034” in its research database.

“According to the latest research study, the global point-of-care molecular diagnostics market size was valued at around USD 8.46 billion in 2024. The market is expected to grow at a CAGR of 8.70% and is anticipated to reach a value of USD 17.94 billion by 2034.”

Get a Free Sample PDF of this Research Report for more Insights - https://www.zionmarketresearch.com/sample/point-of-care-molecular-diagnostic-market

Point-Of-Care Molecular Diagnostics Market Overview:

The point-of-care molecular diagnostic market covers the specialized healthcare ecosystem focused on medical testing platforms that execute nucleic acid amplification and genetic analysis directly near the patient's bedside or treatment facility. Unlike classic laboratory-based molecular diagnostic equipment that requires transportation of biological samples to centralized testing facilities, these microfluidic systems provide high-precision pathogen and genetic sequencing intelligence within minutes. Utilizing automated assays, portable cartridge readers, and sophisticated diagnostic chips, these medical setups enable physicians to detect viral, bacterial, and genomic structural flags efficiently inside local clinics, emergency departments, and remote decentralized zones.

The market dynamics are heavily fueled by an increasing global prevalence of acute infectious diseases and chronic respiratory ailments requiring rapid clinical identification. Structural transformations within the marketplace are driven by the fast technological optimization of isothermal amplification methods and the integration of smartphone-enabled data-sharing platforms. On the contrary, high development costs for complex microfluidic cartridges and rigid regulatory approval cycles present significant, ongoing challenges to broad entry. Emerging opportunities are highly concentrated in the adoption of decentralized multi-pathogen panel systems, while managing severe supply chain disruptions and localized alternative screening method competition remains a steady industry challenge.

Report Scope:

Report Attribute	Report Details
Market Size in 2024	USD 8.46 Billion
Market Forecast in 2034	USD 17.94 Billion
Growth Rate	CAGR of 8.70%
Base Year	2024
Forecast Years	2025- 2034
Key Companies Covered	Reliance Industries Limited, INEOS Group Limited, Exxon Mobil Corporation, Dow Inc., Formosa Plastics Corporation, SABIC (Saudi Basic Industries Corporation), Chevron Phillips Chemical Company, SK Global Chemical Co. Ltd., Royal Dutch Shell plc, BASF SE, LyondellBasell Industries N.V., Idemitsu Kosan Co. Ltd., Mitsui Chemicals Inc., Braskem S.A., TotalEnergies SE, and others.
Segments Covered	By Product Type, By Technology, By Application, By End-User, By Distribution Channel, and By Region
Regions Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Customization Scope	Avail customized purchase options to meet your exact research needs.

Directly Purchase a Copy of the Report | Quick Delivery Available - https://www.zionmarketresearch.com/buynow/su/point-of-care-molecular-diagnostic-market

Key Insights from Primary Research

• As per the analysis, the point-of-care molecular diagnostics market share is likely to grow at a CAGR of around 8.70% between 2025 and 2034.
• The point-of-care molecular diagnostics market size was worth around $8.46 billion in 2024 and is estimated to hit approximately $17.94 billion by 2034. Due to a variety of driving factors, the market is predicted to rise at a significant rate.
• The market is driven by the urgent clinical demand to lower patient hospital stay durations, combined with a rising adoption of automated molecular testing inside local community health centers.
• Based on the product type, the reagents and consumables segment dominated the market with a share of over 62% because decentralized diagnostic operations require a continuous supply of single-use, assay-specific testing cartridges for every patient sample tested.
• Based on the technology, the polymerase chain reaction segment dominated the market with a share of over 48% because PCR systems represent the historical gold standard for genetic replication accuracy and display maximum trust among medical professionals globally.
• Based on the application, the infectious disease testing segment held the largest share of approximately 60% due to the massive continuous global requirement for tracking viral influenza, sexually transmitted infections, and multidrug-resistant bacterial strains inside outpatient facilities.
• Based on the end-user, the hospitals and clinics segment dominated with a share of 52% because emergency diagnostic departments require instant molecular results to establish strict patient isolation protocols and prescribe targeted antiviral medication.
• Based on the distribution channel, the direct sales segment dominated the market with a share of 55% as large medical institutions prefer long-term procurement agreements directly with original biotechnology manufacturers to secure stable bulk pricing.
• North America dominated the global market with a share of 42% in 2024 due to extensive healthcare IT funding infrastructure, highly favorable clinical reimbursement programs, and deep technological market penetration by top diagnostic biotechnology corporations.

Point-Of-Care Molecular Diagnostics Market: Dynamics

Growth Drivers

How is the global expansion of decentralized outpatient centers driving market adoption?

The aggressive global establishment of neighborhood immediate care centers, walk-in clinics, and decentralized emergency rooms acts as the primary engine driving current market adoption rates. Modern healthcare providers are heavily focusing on shifting general diagnostic tasks away from overcrowded central hospital laboratories to speed up clinical decision pathways and optimize staff workflows. Point-of-care molecular systems perfectly support this structural transition by delivering high-accuracy genetic pathogen results right inside local clinics, allowing doctors to start targeted antibiotic therapies immediately during the initial patient visit.

Furthermore, the rising global frequency of seasonal respiratory viral outbreaks provides a highly reliable secondary growth stream for specialized biotechnology providers. When unexpected viral infections surge across communities, traditional centralized testing infrastructure frequently experiences severe sample backlogs, which delay critical medical containment efforts. Outfitting local community pharmacies and public health outposts with portable molecular cartridge platforms eliminates sample transport logistics, ensuring steady system volume expansion across global diagnostic distribution networks.

Restraints

What challenges do high technological development expenses and rigid regulatory protocols pose to market progress?

The significant upfront capital and intensive research funding required to design stable microfluidic testing cartridges and specialized optical readers remain a notable structural barrier to faster market penetration. Developing a point-of-care molecular assay involves precisely embedding complex chemical reagents and nucleic acid extraction controls into a miniature, consumer-friendly plastic shell. For emerging medical technology startups or smaller chemical companies, these continuous high manufacturing engineering costs can limit initial project development and delay product scale-up.

Additionally, navigating the highly strict approval frameworks enforced by international medical regulatory agencies adds layers of financial risk to standard business plans. Companies must execute exhaustive multi-center clinical trials to fully demonstrate that their portable molecular platforms provide identical diagnostic accuracy compared to massive, centralized laboratory infrastructure. These prolonged verification workflows consume vital financial resources, which can strain profit margins and slow down the global commercial rollout of new multi-pathogen testing systems.

Opportunities

Can the strategic integration of next-generation isothermal amplification systems unlock new revenues?

The rapid technological refinement and commercialization of alternative isothermal nucleic acid amplification systems offer an exceptional avenue for long-term market value expansion. Unlike traditional polymerase chain reaction tools that depend on continuous, high-precision thermal cycling components to replicate DNA structures, isothermal methods operate effectively at a single constant temperature. This technological optimization allows manufacturers to build lighter, battery-powered diagnostic readers that are significantly cheaper to assemble, making high-precision molecular testing highly accessible to low-resource rural fields.

Moreover, the growing integration of advanced multi-pathogen syndromic panels presents an excellent opportunity to capture premium clinical margins. Modern medical providers are actively seeking comprehensive cartridge setups that can screen a single patient's nasal swab for a wide group of similar-looking viral illnesses simultaneously. Delivering these unified testing solutions helps diagnostic brands distinguish their inventory from simple single-target tests, capture higher per-test reimbursement values, and create stable recurring contract revenues through continuous institutional cartridge sales.

Challenges

How does intense price competition from cheap immunoassay tests and strict supply chain risks impact the industry?

The global point-of-care molecular diagnostic sector faces persistent market challenges arising from the widespread availability of low-cost rapid lateral flow immunoassay strips. Although traditional antigen tests display much lower diagnostic sensitivity and frequently miss early-stage infections, they retail at a fraction of the cost of a molecular assay cartridge. In cost-sensitive developing medical sectors, hospital administrators often choose these basic immunoassay formats to handle high patient volumes, making it difficult for premium molecular device suppliers to scale operations.

At the same time, maintaining specialized temperature-controlled logistics networks for sensitive molecular enzyme reagents creates a continuous supply chain challenge for global distributors. Many high-performance diagnostic assays use biological components that must stay within rigid temperature ranges during transit to prevent product degradation before final clinic use. Any transport disruption, warehouse power failure, or extreme weather event during maritime or air shipment can ruin entire cartridge batches, leading to product waste and lowering long-term brand reliability.

Browse the full “Point-Of-Care Molecular Diagnostics Market By Product Type (Instruments and Analyzers, Reagents and Consumables, Software and Services), By Technology (Polymerase Chain Reaction, Isothermal Amplification, Hybridization, Next-Generation Sequencing), By Application (Infectious Disease Testing, Oncology and Cancer Screening, Cardiology, Neurological Disorders, Sexual Health and Sexually Transmitted Infections), By End-User (Hospitals and Clinics, Diagnostic Laboratories, Ambulatory Care Centers, Home Care Settings, Pharmacies), By Distribution Channel (Direct Sales, Distributors and Dealers, Online Retail), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034” Report at https://www.zionmarketresearch.com/report/point-of-care-molecular-diagnostic-market

Point-Of-Care Molecular Diagnostics Market: Segmentation

The Point-of-Care Molecular Diagnostic market is segmented by product type, technology, application, end-user, distribution channel, and region.

Based on Product Type, the Point-of-Care Molecular Diagnostic market is divided into instruments and analyzers, reagents and consumables, and software and services. The Reagents and Consumables segment represents the absolute dominant category within the global market. The dominance of this segment is driven by the highly recurring nature of diagnostic cartridge consumption, where clinical centers must purchase fresh single-use test modules for every individual assay performed. This continuous operational demand helps drive the overall market forward by sustaining high-capacity production orders for chemical reagent suppliers globally. The second most dominant category is Instruments and Analyzers, which covers the primary capital purchases of portable electronic readers and optical base units required to analyze the test cartridges.

Based on Technology, the Point-of-Care Molecular Diagnostic market is divided into polymerase chain reaction, isothermal amplification, hybridization, and next-generation sequencing. The Polymerase Chain Reaction segment stands as the most dominant technology group in the market. Its leading position is due to its long history of validation, exceptional genomic replication sensitivity, and widespread adoption as the regulatory baseline for tracking viral pathogens. The second most dominant category is Isothermal Amplification, which is experiencing high growth because it operates at a stable constant temperature, allowing medical technology brands to engineer cheaper, battery-operated field kits.

Based on Application, the Point-of-Care Molecular Diagnostic market is divided into infectious disease testing, oncology and cancer screening, cardiology, neurological disorders, and sexual health and sexually transmitted infections. The Infectious Disease Testing segment acts as the leading application area, holding more than half of the global market share. The dominance of this segment is powered by the urgent clinical need to identify transmissible viral influenza, respiratory pathogens, and nosocomial bacterial infections immediately at the bedside to avoid cross-infection. The second most dominant category is Sexual Health and Sexually Transmitted Infections, driven by the expanding rollout of private, fast screening panels within public health clinics.

Based on End-User, the Point-of-Care Molecular Diagnostic market is divided into hospitals and clinics, diagnostic laboratories, ambulatory care centers, home care settings, and pharmacies. The Hospitals and Clinics segment represents the dominant end-user group due to high patient emergency footfall and the vital clinical requirement to obtain immediate molecular insights to guide targeted antibiotic selections. The second most dominant end-user category is Diagnostic Laboratories, which deploy these systems near pickup desks to quickly process high-priority, quick-turnaround diagnostic requests.

Based on Distribution Channel, the Point-of-Care Molecular Diagnostic market is divided into direct sales, distributors and dealers, and online retail. The Direct Sales segment is the most dominant distribution channel, as major healthcare systems and nationwide laboratory groups enter direct long-term bulk supply agreements with manufacturers to guarantee reliable cartridge delivery schedules. The second most dominant category is Distributors and Dealers, which are heavily relied upon to manage local distribution, inventory supply, and technical assistance across decentralized rural clinics.

Regional Scope:

Why will North America continue to dominate the global market during the projection period?

North America is projected to maintain its leading position in the global Point-of-Care Molecular Diagnostic market through the forecast period, supported by an advanced healthcare infrastructure and high spending on cutting-edge biotechnology systems. The region's dominance is primarily driven by the United States, where widespread corporate integration of electronic health records, high availability of clinical financing, and helpful medical reimbursement policies keep diagnostic demand exceptionally strong. Furthermore, the presence of major international medical technology giants and advanced biotechnology hubs ensures efficient product innovation and smooth supply lines across domestic healthcare networks. The ongoing structural modification of outpatient clinics to include rapid molecular testing platforms also helps regional facilities reduce patient wait times while maintaining consistent testing service volumes.

The Asia-Pacific region is anticipated to experience the highest growth rate during the forecast period. Countries like China and India are undergoing massive healthcare transformations, with governments focusing heavily on upgrading local health centers and expanding decentralized medical access. The rapid expansion of regional middle-class populations, combined with growing public awareness regarding early disease diagnosis, drives high demand for precision molecular diagnostics. Moreover, rising state funding aimed at tracking infectious tropical diseases and managing large-scale rural healthcare initiatives creates immense demand for portable, low-cost isothermal diagnostic setups. The entry of major international medical device firms and the rapid modernization of local community clinics into connected digital health hubs further accelerate the regional market's expansion.

Recent Developments

• In January 2026, Abbott Laboratories completed the strategic acquisition of a prominent microfluidic diagnostic company to integrate advanced multiplexed respiratory panels into its handheld molecular testing portfolio.
• In October 2025, Roche Diagnostics announced a substantial investment in expanding its automated cartridge manufacturing facilities to address the escalating global demand for decentralized oncology assays.
• In April 2026, Cepheid introduced a new line of fully eco-certified, high-throughput point-of-care molecular diagnostic systems designed to run multiple independent PCR tests simultaneously inside compact clinic layouts.

Request For Customization on This Report as Per Your Requirements - https://www.zionmarketresearch.com/custom/10502

Point-Of-Care Molecular Diagnostics Market: Competitive Landscape

The report contains qualitative and quantitative research on the global point-of-care molecular diagnostics market, as well as detailed insights and development strategies employed by the leading competitors.

Some of the leading players in the global point-of-care molecular diagnostics market include;        

• Abbott Laboratories
• Roche Diagnostics
• bioMérieux
• Danaher Corporation
• Becton Dickinson and Company
• Hologic Incorporated
• Qiagen
• Meridian Bioscience
• Cepheid (a Danaher company)
• Chembio Diagnostics

What are the key trends in the Point-of-Care Molecular Diagnostic Market?

The Rising Proliferation of Smartphone-Connected Diagnostic Readers

A major trend impacting the market is the consumer and clinical demand for smart, digitally integrated molecular testing devices. Modern manufacturers are actively designing ultra-portable cartridge readers that pair with smartphones via Bluetooth, enabling automatic uploading of secure patient test records directly to centralized electronic hospital databases.

The Rapid Integration of CRISPR Technology into Portable Molecular Testing

Modern biotechnology facilities are changing fast due to the adoption of CRISPR-based gene-editing tools for pathogen detection. This engineering trend allows developers to build highly sensitive paper-based molecular strips that can flag specific viral genetic sequences without requiring heavy optical machinery.

The global point-of-care molecular diagnostics market is segmented as follows:

By Product Type

• Instruments and Analyzers
• Reagents and Consumables
• Software and Services

By Technology

• Polymerase Chain Reaction
• Isothermal Amplification
• Hybridization
• Next-Generation Sequencing

By Application

• Infectious Disease Testing
• Oncology and Cancer Screening
• Cardiology
• Neurological Disorders
• Sexual Health and Sexually Transmitted Infections

By End-User

• Hospitals and Clinics
• Diagnostic Laboratories
• Ambulatory Care Centers
• Home Care Settings
• Pharmacies

By Distribution Channel

• Direct Sales
• Distributors and Dealers
• Online Retail

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Southeast Asia
• The Middle East & Africa
  • GCC
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

Request Free Brochure of the Global Point-Of-Care Molecular Diagnostics Market @ https://www.zionmarketresearch.com/requestbrochure/point-of-care-molecular-diagnostic-market

Key Questions Answered in This Report:

• What is the point-of-care molecular diagnostics market?
• What key factors will influence the point-of-care molecular diagnostics market growth from 2025 to 2034?
• What will be the value of the point-of-care molecular diagnostics market during 2025–2034?
• What will be the CAGR value of the point-of-care molecular diagnostics market during 2025–2034?
• Which region will contribute the most to the point-of-care molecular diagnostics market?
• Which are the major players driving the growth of the point-of-care molecular diagnostics market?
• What can be expected from the global point-of-care molecular diagnostics market report?
• Which region is expected to witness the fastest growth in the point-of-care molecular diagnostics market during the forecast period?
• What investment or partnership opportunities exist in the point-of-care molecular diagnostics market?
• How are market trends and consumer preferences evolving in the point-of-care molecular diagnostics market?

Browse Other Related Research Reports from Zion Market Research

• Wearable Medical Device Market Size, Share, Trends, By Device Type (Diagnostic Devices, Therapeutic Devices, Drug Delivery Devices), By Application (Remote Patient Monitoring, Sports & Fitness, Home Healthcare, Chronic Disease Management), By End User (Hospitals & Clinics, Homecare Settings, Sports & Fitness Centres, Research Institutions), By Connectivity Technology (Bluetooth, Wi-Fi, NFC, Cellular), By Region, and Forecast 2026 - 2034
• Lung Stent Market By Product Type (Silicone Stents, Metal Stents, Hybrid Stents, and Biodegradable Stents), By Indication (Malignant Airway Obstruction, Benign Airway Stenosis, Tracheobronchomalacia, Fistulas and Perforations, and Post-Transplant Complications), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Academic & Research Institutions), By Material (Nitinol, Stainless Steel, Silicone, Polyurethane, and Biodegradable Polymers), and By Region -Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034
• Tennis Wheelchair Market By Product Type (Power Wheelchairs and Manual Wheelchairs), By Material (Steel, Carbon Fiber, and Aluminum), By End-User (Recreational Players and Professional Athletes), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034
• Dermatology Diagnostic Devices Market By Type (Handheld Devices, Imaging Systems, and Laboratory Diagnostic Devices), By Technology (Optical Coherence Tomography (OCT), Dermoscopy, Ultrasound Imaging, Confocal Microscopy, and Molecular & Genetic Diagnostic Techniques), By Application (Hospitals & Clinics, Dermatology Centers, and Diagnostic Laboratories), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034
• Laboratory Plasticware Market By Material (Polystyrene, High-Density Polyethylene (HDPE), Low-Density Polyethylene (LDPE), Polymethylpentene (PMP), Polyvinyl Chloride (PVC), and Others), By End-User (Pharmaceutical & Biotechnology Companies, Diagnostic Centers, Research & Academic Institutes, Hospitals, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034

About Zion Market Research:

Zion Market Research is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Zion Market Research are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Contact Us:

Zion Market Research

USA/Canada Toll Free:  1 (855) 465-4651 | Newark: 1 (302) 444-0166

India: +91 7768 006 007 | +91 7768 006 008

Email: sales@zionmarketresearch.com | Web: https://www.zionmarketresearch.com/

Follow Us on - LinkedIn | X | Facebook | Pinterest | YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.